Journal of orthopaedic trauma · 2012
Is surgical fixation for stress-positive unstable ankle fractures cost effective? Results of a multicenter randomized control trial.
СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Slobogean Gerard P, Marra Carlo A, Sadatsafavi Mohsen, Sanders David W, Canadian Orthopedic Trauma Society
Аннотация
OBJECTIVES: A recent multicenter randomized control trial demonstrated similar quality of life at 1 year after open reduction and internal fixation (ORIF) compared with nonoperative treatment for stress-positive unstable isolated lateral malleolar fractures. We sought to determine the cost-effectiveness of ORIF compared with nonoperative management of these isolated lateral malleolar fractures.
DESIGN: Cost-utility analysis using decision tree and Markov modeling based on data from a prospective randomized control trial and previously published literature. A single-payer perspective with 1-year and lifetime time horizons was adopted.
SETTING: Clinical trial data from 6 Canadian level I trauma hospitals.
INTERVENTION: Lateral malleolus ORIF versus nonoperative treatment.
MAIN OUTCOME MEASUREMENTS: Incremental cost-effectiveness ratio (ICER).
RESULTS: The base case 1-year ICER of the ORIF treatment was $205,090 per quality-adjusted life year gained, favoring nonoperative treatment. For the lifetime time horizon, ORIF becomes the preferred treatment with an ICER of $16,404 per quality-adjusted life year gained. This conclusion is stable provided ORIF lowers the lifetime incidence of ankle arthrosis by >3% compared with nonoperative treatment. Probabilistic sensitivity analysis demonstrated that 33% of model simulations favored ORIF in the 1-year time horizon and 65% of simulations in the lifetime time horizon.
CONCLUSIONS: From a single-payer governmental perspective, ORIF does not seem to be cost effective in the 1-year time horizon; however, if operative fixation decreases the lifetime incidence of posttraumatic ankle arthrosis by >3%, then ORIF becomes the economically preferred treatment.
LEVEL OF EVIDENCE: Economic Level II. See Instructions for Authors for a complete description of levels of evidence.
DESIGN: Cost-utility analysis using decision tree and Markov modeling based on data from a prospective randomized control trial and previously published literature. A single-payer perspective with 1-year and lifetime time horizons was adopted.
SETTING: Clinical trial data from 6 Canadian level I trauma hospitals.
INTERVENTION: Lateral malleolus ORIF versus nonoperative treatment.
MAIN OUTCOME MEASUREMENTS: Incremental cost-effectiveness ratio (ICER).
RESULTS: The base case 1-year ICER of the ORIF treatment was $205,090 per quality-adjusted life year gained, favoring nonoperative treatment. For the lifetime time horizon, ORIF becomes the preferred treatment with an ICER of $16,404 per quality-adjusted life year gained. This conclusion is stable provided ORIF lowers the lifetime incidence of ankle arthrosis by >3% compared with nonoperative treatment. Probabilistic sensitivity analysis demonstrated that 33% of model simulations favored ORIF in the 1-year time horizon and 65% of simulations in the lifetime time horizon.
CONCLUSIONS: From a single-payer governmental perspective, ORIF does not seem to be cost effective in the 1-year time horizon; however, if operative fixation decreases the lifetime incidence of posttraumatic ankle arthrosis by >3%, then ORIF becomes the economically preferred treatment.
LEVEL OF EVIDENCE: Economic Level II. See Instructions for Authors for a complete description of levels of evidence.